Medicare Part D coverage · 84 · RxCUI 1356979
84 HR estradiol 0.00156 MG/HR Transdermal System [Minivelle]
Per the CMS 2026 Part D formulary file, 84 HR estradiol 0.00156 MG/HR Transdermal System [Minivelle] is covered by 15 Medicare Part D plans (0.3% of enrollable products), averaging Tier 4, with prior authorization required on 100% of covering formularies.
- 0.3%
- Plan coverage
- 15
- Plans covering
- T4
- Avg tier
- 100%
- Prior auth required
What the CMS Formulary Data Shows for 84 HR estradiol 0.00156 MG/HR Transdermal System [Minivelle]
Per the CMS 2026 Part D formulary file, 84 HR estradiol 0.00156 MG/HR Transdermal System [Minivelle] (RxNorm concept RXCUI 1356979, generic name 84) appears on 2 distinct formulary files spanning 15 Medicare Part D plan offerings - 0.3% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 4 to Tier 4, with a cross-plan average of Tier 4.
Real-world access to 84 HR estradiol 0.00156 MG/HR Transdermal System [Minivelle] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 666 Part D beneficiaries filled 84 HR estradiol 0.00156 MG/HR Transdermal System [Minivelle] in 2023, with total plan-and-beneficiary spending of $1,416,918 and an average per-beneficiary annual cost of $2,127.50. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 84 HR estradiol 0.00156 MG/HR Transdermal System [Minivelle] today.
Coverage Details
- Formularies covering
- 2
- Plans covering
- 15
- Coverage rate
- 0.3%
- Tier range
- Tier 4, Non-Preferred
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 100% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 666
- Total spending
- $1,416,918
- Avg per beneficiary
- $2,127.50
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering 84 HR estradiol 0.00156 MG/HR Transdermal System [Minivelle]
15 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Personal Choice 65 Achieve Rx (PPO) | QCC Insurance Company | T4 | Yes | $0 | PA |
| Keystone 65 Focus Rx (HMO-POS) | Keystone Health Plan East, Inc. | T4 | Yes | $0 | PA |
| Keystone 65 Focus Rx (HMO-POS) | Keystone Health Plan East, Inc. | T4 | Yes | $0 | PA |
| Keystone 65 Basic Rx (HMO) | Keystone Health Plan East, Inc. | T4 | Yes | $0 | PA |
| AmeriHealth Medicare Core (PPO) | Amerihealth Insurance Company OF NEW Jersey | T4 | Yes | $0 | NJ |
| AmeriHealth Medicare Ultimate (PPO) | Amerihealth Insurance Company OF NEW Jersey | T4 | Yes | $0 | NJ |
| Keystone 65 Essential Rx (HMO-POS) | Keystone Health Plan East, Inc. | T4 | Yes | $31.00 | PA |
| AmeriHealth Medicare Enhanced (PPO) | Amerihealth Insurance Company OF NEW Jersey | T4 | Yes | $36.00 | NJ |
| Keystone 65 Select Rx (HMO) | Keystone Health Plan East, Inc. | T4 | Yes | $47.00 | PA |
| Keystone 65 Preferred Rx (HMO) | Keystone Health Plan East, Inc. | T4 | Yes | $59.70 | PA |
| Keystone 65 Select Rx (HMO) | Keystone Health Plan East, Inc. | T4 | Yes | $63.50 | PA |
| Keystone 65 Preferred Rx (HMO) | Keystone Health Plan East, Inc. | T4 | Yes | $79.70 | PA |
| Personal Choice 65 Plus Rx (PPO) | QCC Insurance Company | T4 | Yes | $81.20 | PA |
| Personal Choice 65 Rx (PPO) | QCC Insurance Company | T4 | Yes | $102.20 | PA |
| Personal Choice 65 Rx (PPO) | QCC Insurance Company | T4 | Yes | $112.70 | PA |
Frequently Asked Questions
Is 84 HR estradiol 0.00156 MG/HR Transdermal System [Minivelle] covered by Medicare Part D?
Yes, 84 HR estradiol 0.00156 MG/HR Transdermal System [Minivelle] is covered by 15 Medicare Part D plans (0.3% of all Part D formularies).
What tier is 84 HR estradiol 0.00156 MG/HR Transdermal System [Minivelle] on Medicare Part D plans?
84 HR estradiol 0.00156 MG/HR Transdermal System [Minivelle] averages Tier 4 across Part D plans, ranging from Tier 4 to Tier 4.
Does 84 HR estradiol 0.00156 MG/HR Transdermal System [Minivelle] require prior authorization?
100% of Part D formularies require prior authorization for 84 HR estradiol 0.00156 MG/HR Transdermal System [Minivelle]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on 84 HR estradiol 0.00156 MG/HR Transdermal System [Minivelle]?
In 2023, total Medicare Part D spending on 84 HR estradiol 0.00156 MG/HR Transdermal System [Minivelle] was $1,416,918, covering 666 beneficiaries. The average spend per beneficiary was $2,127.50.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- dihydroergotamine mesylate 0.5 MG/ACTUAT Metered Dose Nasal Spray T4
- 0.5 ML darbepoetin alfa 0.2 MG/ML Prefilled Syringe [Aranesp] T4
- amoxicillin 250 MG / omeprazole 10 MG / rifabutin 12.5 MG Delayed Release Oral Capsule [Talicia] T4
- timolol hemihydrate 5 MG/ML Ophthalmic Solution [Betimol] T4
- deflazacort 18 MG Oral Tablet [Jaythari] T4
- bepotastine besilate 15 MG/ML Ophthalmic Solution [Bepreve] T4
Similar prior-authorization rate
- azathioprine 50 MG Oral Tablet 100% PA
- 0.5 ML hepatitis B surface antigen vaccine 0.04 MG/ML Prefilled Syringe [Heplisav-B] 100% PA
- 0.5 ML hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] 100% PA
- 1 ML hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] 100% PA
- sotagliflozin 200 MG Oral Tablet [Inpefa] 100% PA
- mycophenolate mofetil 250 MG Oral Capsule 100% PA